Blastic Plasmacytoid Dendritic Cell Neoplasm: Still an Enigma

  • Neha Singh
  • Narendra Agrawal
  • Poojan Agarwal
  • Anurag Mehta
Correspondence

Notes

Compliance with Ethical Standards

Conflict of interest

The authors state that there is no conflict of interest present.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Petrella T, Bagot M, Willemze R et al (2005) Blastic NK-cell lymphomas (agranular CD4+CD56+hematodermic neoplasms): a review. Am J Clin Pathol 123:662CrossRefPubMedGoogle Scholar
  2. 2.
    Chaperot L, Bendriss N, Manches O et al (2001) Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97:3210CrossRefPubMedGoogle Scholar
  3. 3.
    Reizis B, Bunin A, Ghosh HS et al (2011) Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol 29:163CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Julia F, Petrella T, Beylot-Barry M et al (2013) Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 169:579CrossRefPubMedGoogle Scholar
  5. 5.
    Falcone U, Sibai H, Deotare U (2016) A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm. Crit Rev Oncol Hematol 107:156–162CrossRefPubMedGoogle Scholar
  6. 6.
    Lucioni M, Novara F, Fiandrino G et al (2011) Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood 118:4591CrossRefPubMedGoogle Scholar
  7. 7.
    Rauh MJ, Rahman F, Good D et al (2012) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: case series and literature review. Leuk Res 36:81CrossRefPubMedGoogle Scholar
  8. 8.
    Shapiro R, Sangle N, Keeney M, Chin-Yee IH, Hsia CC et al (2015) Blastic plasmacytoid dendritic cell neoplasm: a review of diagnosis, pathology, and therapy. J Cell Sci Ther S8:008.  https://doi.org/10.4172/2157-7013.S8-008 Google Scholar
  9. 9.
    Petrella T, Meijer CJ, Dalac S, Willemze R, Maynadié M et al (2004) TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NKcell lymphomas) and leukemia cutis. Am J Clin Pathol 122:307–313CrossRefPubMedGoogle Scholar
  10. 10.
    Sangle NA, Schmidt RL, Patel JL, Medeiros LJ, Agarwal AM et al (2014) Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. Mod Pathol 27:1137–1143CrossRefPubMedGoogle Scholar
  11. 11.
    Julia F, Dalle S, Duru G, Balme B, Vergier B et al (2014) Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol 38:673–680CrossRefPubMedGoogle Scholar
  12. 12.
    Facchetti F, Jones DM, Petrella T (2008) Blastic plasmacytoid dendritic cells neoplasm, WHO classification of tumours of hematopoietic and lymphoid tissues. IARC Press, Lyon, pp 145–147Google Scholar
  13. 13.
    Martin-Martin L, Lopez A, Vidriales B, Caballero MD, Rodrigues AS et al (2015) Classification and clinical behaviour of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget 6:19204–19216CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Angelot-Delettre F, Garnache-Ottou F (2012) Blastic plasmacytoid dendritic cell neoplasm. Blood 120:2784CrossRefPubMedGoogle Scholar
  15. 15.
    Taylor J, Kim SS, Stevenson KE et al (2013) Loss-of-function mutations in the splicing factor ZRSR2 are common in blastic plasmacytoid dendritic cell neoplasm and have male predominance [ASH abstract 741]. Blood 122(21):741Google Scholar
  16. 16.
    Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P et al (2013) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 98:239–246CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tsagarakis NJ, Kentrou NA, Papadimitrou KA, Pagoni M, Kokkini G, for the Hellenic Dendritic Cell Leukemia Study Group et al (2010) Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res 34:438–446CrossRefPubMedGoogle Scholar
  18. 18.
    Poret E, Vidal C, Desbrosses Y et al (2015) How to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) patients: results on 86 patients of the French BPDCN network. Blood 126:456Google Scholar
  19. 19.
    Pagano L, Valentini CG, Pulsoni A et al (2013) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 98:239CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Julia F, Petrella T, Beylot-Barry M (2013) Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 169(3):579–586CrossRefPubMedGoogle Scholar
  21. 21.
    Frankel AE, Woo JH, Ahn C (2014) Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 124(3):385–392CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  • Neha Singh
    • 1
  • Narendra Agrawal
    • 2
  • Poojan Agarwal
    • 1
  • Anurag Mehta
    • 1
  1. 1.Department of Pathology and Lab ServicesRajiv Gandhi Cancer Institute and Research CenterRohiniIndia
  2. 2.Department of Hemato-OncologyRajiv Gandhi Cancer Institute and Research CenterRohiniIndia

Personalised recommendations